Quick Answer
Lexeo Therapeutics, Inc. reported Operating Income Loss of -$109.26 million for the year ending 2025.
- Lexeo Therapeutics, Inc. showed a decrease of -3.3% in Operating Income Loss from 2024 to 2025.
- This data is from Lexeo Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2022: -$17.48 million | Q1 2023: -$19.29 million | Q2 2023: -$13.98 million | Q3 2023: -$20.27 million | Q1 2024: -$23.29 million | Q2 2024: -$23.55 million | Q3 2024: -$31.54 million | Q1 2025: -$33.81 million | Q2 2025: -$30.69 million | Q3 2025: -$21.65 million.
- Over the full 4 years of available data (2022 to 2025), Lexeo Therapeutics, Inc.'s Operating Income Loss has declined by 80.6%.
- Historical annual values: Fiscal year 2025: -$109.26 million | Fiscal year 2024: -$105.77 million | Fiscal year 2023: -$68.51 million | Fiscal year 2022: -$60.51 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: